No results for ‘’
Hindustan Bio Sciences Ltd
₹8.70
(1.75%)
Sat, 30 May 2026, 00:09 pm
Health Technology
Pharmaceuticals: Major
24.5KHindustan Bio Sciences Price to Cash Flow Ratio
| Particulars | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 0 | 13.30 | 0 | 288.75 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8.76 | 18.25 | 0 | 0 | 0 | 129 | 71.08 |
| Price to book ratio | 0.45 | 0.13 | 0.33 | 0.23 | 0.20 | 0.10 | 0.11 | 0.20 | 0.56 | 0.45 | 0.35 | 0.45 | 0.66 | 2.36 | 5.50 | 7.30 | 9.24 | 7.91 |
| Price to sales ratio | 3.06 | 0.36 | 0.86 | 0.63 | 0.77 | 0.24 | 0.40 | 1.86 | 2.16 | 1.92 | 0.70 | 0.27 | 0.76 | 3.01 | 10.05 | 6.04 | 7.08 | 8.80 |
| Price to cash flow ratio | 21.39 | 0 | 0 | 8.66 | 0 | 56.88 | 0 | 0 | 6.30 | 0 | 0 | 0 | 1.80 | 5.51 | 0 | 0 | 0 | 264.02 |
| Enterprise value | 43.54M | 11.67M | 32.19M | 19.66M | 21.28M | 10.25M | 11.68M | 21.61M | 36.33M | 32.06M | 22.7M | 41.46M | 38.76M | 49.17M | 64.83M | 78.13M | 99.53M | 96.49M |
| Enterprise value to EBITDA ratio | 32.07 | 3.44 | 6.83 | 3.26 | 10.53 | 0 | 0 | 0 | 0 | 0 | 0 | 31 | 28.68 | 0 | 0 | 0 | 165.81 | 94.51 |
| Debt to equity ratio | 0.01 | 0 | 0.01 | 0.01 | 0.01 | 0.02 | 0.05 | 0.14 | 0.20 | 0.30 | 0.76 | 1.56 | 1.16 | 1.42 | 2.75 | 3.29 | 3.18 | 2.77 |
| Return on equity % | 0 | 0.96 | -1.98 | 0.08 | -0.85 | -7.34 | -11.13 | -18.99 | -35.60 | -10.74 | -71.30 | 5.22 | 3.67 | -52.96 | -49.49 | -5.28 | 7.43 | 11.78 |
Hindustan Bio Sciences Ltd Price to Cash Flow Ratio
The Hindustan Bio Sciences Ltd Price to Cash Flow Ratio is a key financial metric used by investors to evaluate Hindustan Bio Sciences Ltd's valuation, profitability, and overall financial performance. Tracking the Hindustan Bio Sciences Ltd Price to Cash Flow Ratio helps investors understand whether the stock is undervalued, fairly valued, or trading at a premium compared to its historical performance and industry peers.
Hindustan Bio Sciences Ltd (NSE: , BSE: 532041) is currently trading at ₹8.70, with a market capitalization of ₹87.64M. As a leading company in the Health technology sector and Pharmaceuticals: major industry, monitoring the Hindustan Bio Sciences Ltd Price to Cash Flow Ratio is essential for fundamental analysis.
Hindustan Bio Sciences Ltd Price to Cash Flow Ratio Current Value
The current Hindustan Bio Sciences Ltd Price to Cash Flow Ratio stands at 264.02.
The latest Hindustan Bio Sciences Ltd Price to Cash Flow Ratio has increased compared to the previous period, indicating rising valuation or improved investor sentiment.
Hindustan Bio Sciences Ltd Price to Cash Flow Ratio Historical Trend
The Hindustan Bio Sciences Ltd Price to Cash Flow Ratio has shown the following historical trend:
- 2024: 264.02
- 2023: 0
- 2022: 0
- 2021: 0
- 2020: 5.51
The recent rise in Hindustan Bio Sciences Ltd Price to Cash Flow Ratio suggests strengthening valuation trends and improving market sentiment.
What Hindustan Bio Sciences Ltd Price to Cash Flow Ratio Indicates for Investors
The Hindustan Bio Sciences Ltd Price to Cash Flow Ratio plays a crucial role in understanding the company's financial health and valuation.
The P/CF ratio indicates how much investors pay for company cash flow.
Hindustan Bio Sciences Ltd Price to Cash Flow Ratio Analysis Summary
The Hindustan Bio Sciences Ltd Price to Cash Flow Ratio remains a crucial metric for evaluating the company's valuation and financial stability. Investors tracking Hindustan Bio Sciences Ltd Price to Cash Flow Ratio should also monitor related metrics such as P/E, P/B, EV/EBITDA, D/E, and ROE to get a complete fundamental picture.
Regular tracking of Hindustan Bio Sciences Ltd Price to Cash Flow Ratio helps investors make informed decisions based on long-term growth, valuation trends, and financial performance.